Health on MSN1d
What To Know About HR+/HER2- Breast CancerHR+/HER2- breast cancer involves cells that test positive for hormone receptors and negative for HER2 proteins. It's the most ...
GlobalData on MSN1d
AstraZeneca reports positive outcomes from breast cancer combo therapy trialAstraZeneca has reported positive outcomes from a planned interim analysis of the double-blind Phase III SERENA-6 trial of ...
Medpage Today on MSN10h
Melatonin's Anti-Cancer Potential; Prenatal PFAS and Cancer; Anti-Viral Gel for HPVA first-of-its-kind antiviral gel may offer the potential to stop papillomavirus (HPV) infection before it causes cancer. ( ...
In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...
Metronomic capecitabine plus an aromatase inhibitor improved survival outcomes in hormone receptor-positive, HER2-negative ...
Daiichi Sankyo and AstraZeneca’s Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metast ...
AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy ...
AstraZeneca's experimental breast cancer drug camizestrant, when combined with a cyclin-dependent kinase inhibitor, has shown significant improvement in delaying disease progression in patients with ...
Bank of America analysts estimate a peak sales potential of $6 billion for camizestrant across the SERENA-6 and SERENA-4 ...
Regarding patients with HER2-negative, estrogen receptor (ER)-positive breast cancer, the phase 3 KEYNOTE-756 study is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback